Change someone's life today

Donate now

Your donation will get us one step closer to a world where dementia no longer devastates lives.

  • Direct Debit
  • Fundraising Regulator
  • Norton

How will my monthly donation help?

  • £5per month could fund all the equipment and resources needed for one day of a dementia researcher’s vital investigations, helping to improve diagnosis, care and treatment for people affected by the condition.

    Donate £5

  • £10per month could help fund research into how best to care for someone living with dementia, helping carers and health professionals to keep people safe, comfortable, and happy.

    Donate £10

  • £20per month could help fund a research project from one of our Early Career Researchers, supporting a promising researcher at the start of their career and securing the future of dementia research for years to come.

    Donate £20

  • Research is hope

    Alzheimer’s Society research has been truly revolutionary for over 30 years, enabling the first ever treatments to slow down Alzheimer’s disease.

    Our research today will transform dementia diagnosis, treatment and care. But without your kind support this would not be possible.

    Learn more about our research impact

     

     

  • Our fundraising promise

    Alzheimer's Society is a community of supporters, volunteers and staff passionate about making a difference to the lives of people with dementia. Thank you so much for being part of it!

    Read about our fundraising promise

     

     

     

Alzheimer's Society

What is Donanemab?

Donanemab is a treatment for early-stage Alzheimer’s disease that is currently being tested in clinical trials. This drug aims to slow the progression of Alzheimer’s disease by removing amyloid plaques from the brains of people living with the condition. Donanemab is an immunotherapy drug. It works with the body’s immune system to clear amyloid protein build up from the brains of people living with early-stage Alzheimer’s disease. Based on the Phase 3 results, Donanemab appears to slow the progression of Alzheimer’s symptoms by 36 % (as compared with 27% of last year’s breakthrough drug Lecanemab). Promisingly, the trial also demonstrated a 40% slowing in decline of everyday activities such as driving, doing hobbies and managing finances. The results look promising and we await the full results and details of the trial to understand more about this exciting development.

- Alzheimer's Society